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Summary
 Aim The aim of the present study was to apply the Figure of Merit (FOM) concept to 
High Dose Rate (HDR) interstitial brachytherapy treatments delivered for carci-
noma of the cervix at the Kidwai Memorial Institute of Oncology, Bangalore, in 
order to evaluate the radiobiological quality of the implants.
 Materials/Methods Twenty seven patients received external beam radiotherapy, as 50Gy in 25 fractions 
over ﬁ ve weeks, followed by interstitial brachytherapy by the HDR template tech-
nique on a Gammamed HDR machine. Doses were delivered 5mm from the periph-
ery of the implant along the transverse plane. Points in the bladder and rectum, re-
ceiving the maximum dose rate, were used for the evaluation of total dose received 
by these critical organs. BED and FOM values were evaluated for all patients.
 Results Two patients had a rectal FOM value greater than 10. A FOM bladder value of 
higher than 10 was observed in six patients. Only in one patient were FOM val-
ues for both the rectum and bladder found to be above 10. The relationship be-
tween FOM values for the rectum and the bladder indicated that most FOM val-
ues were clustered near the initial portion of the scattergram obtained. For one 
patient the rectal FOM value was above 10, while the FOM for the bladder was 
signiﬁ cantly smaller. In another patient, having a high FOM value for the blad-
der, the FOM value for the rectum was also above the critical value of 10.
 Conclusions Good physical optimization can lead to good radiobiological optimization, as ob-
served in our study. Radiobiology can not improve a bad quality implant. HDR 
interstitial brachytherapy, which gives better geometrical sparing for critical nor-
mal organs such as the rectum and bladder, should be the treatment of choice 
for patients with carcinoma of the cervix. In optimizing treatment for a patient, 
the maximizing of FOM should be supplemented by a comparison of reference 
BED values and new treatments for the tumour, rectum and bladder.
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BACKGROUND
Cancer of uterine cervix is one of the common-
est cancers in developing nations. It comprises 
45% of cancers in women and 25% of all can-
cers, as documented by the cancer registry of 
the Kidwai Memorial Institute of Oncology [1]. 
Seventy percent of these patients present in ad-
vanced stage IIIB. Brachytherapy plays an impor-
tant role in the radiotherapeutic management of 
this malignancy. Intracavitary brachytherapy has 
been practiced since the emergence of radiation 
oncology. However, intracavitary brachytherapy 
for carcinoma of the cervix does not give satis-
factory dose-volume coverage in the sense that 
the lateral pelvic wall does not receive adequate 
dosage. Interstitial brachytherapy with a gynae-
cological template overcomes this drawback and 
has been widely utilized as an important aspect 
of radiotherapy.
Interstitial implants generally involve a range of 
dose rates where variations in the biological ef-
fects of the dose rate are substantial and impor-
tant. In the case of interstitial implants in a clini-
cal setting, the limiting factor is the normal-tissue 
tolerance, which should be used fully to maxi-
mize the possibility of tumour control. The max-
imum dose that can be delivered without unac-
ceptable damage to surrounding normal tissue 
depends, critically, on the dose rate and also on 
the volume of tissue irradiated [2].
High Dose Rate (HDR) brachytherapy was de-
veloped to overcome some of the potential dis-
advantages of low dose rate brachytherapy, such 
as exposure of the professional staff to radiation, 
prolonged treatment times, the need for hospi-
talisation, the risks of anaesthesia, bed immobi-
lization that can lead to thromboembolism, the 
discomfort of vaginal packing and applicators dur-
ing bed immobilization and displacement of the 
applicator [3–8]. HDR brachytherapy has been 
used for more than 30 years world wide. Template 
guided interstitial brachytherapy has been rou-
tinely utilized in the management of carcinoma of 
the cervix and has been extended to HDR brach-
ytherapy techniques. Although three decades of 
experience and literature reports on the use of 
HDR brachytherapy for the treatment of cervi-
cal cancer are available, a wide range of fraction-
ation schedules exist and the treatment optimi-
sation scheme remains unclear [3–8].
The empirical concepts of NSD, CRE and TDF 
were proposed and utilised for many years in spite 
of their limitations [9]. Now, the linear quadratic 
model (LQ) is being used increasingly, to predict 
the biological effects of fractionated radiotherapy 
using different parameters for particular tissues, 
such as a/b, µ, K and T(0) [10–14]. Dale [10] 
has proposed LQ equations for external beam 
therapy, intracavitary brachytherapy and inter-
stitial brachytherapy.
Within the context of the linear-quadratic (LQ) 
model, the parameter which quantiﬁ es the over-
all biological effect on a given tissue is the bio-
logically effective dose (BED). At least two BEDs 
are associated with each treatment and, in prin-
ciple, two or more treatments may be compared 
by reference to their respective tumour and late-
reacting BED values. The BED concept is also of 
potential value in deciding how best to resched-
ule an interrupted treatment.
The parameters which are more directly linked 
with the all important concept of therapeutic 
ratio are, however, the tumour cure probability 
(TCP) and the normal tissue complication prob-
ability (NTCP), neither of which are simply relat-
ed to their respective BEDs. Whilst any treatment 
which (relative to a reference regime) increases 
the tumour BED and reduces the critical tissue 
BED is clearly an improvement over the origi-
nal treatment, the beneﬁ ts of an increased tu-
mour BED which can only be achieved by allow-
ing an increase in the late-reacting BED, is much 
more difﬁ cult to judge. The biological “worth” 
that should be attached to changes in pairs of 
BED values is by no means obvious, as there is 
a secondary dependence on other (usually un-
known) biological parameters. Dale and Sinclair 
[11] have proposed the Figure of Merit (FOM) 
concept with which to rank different treatment 
options. FOM takes into account the BED values 
for tumours and critical organs. Those alterna-
tive treatments which are most like a given ref-
erence treatment will have FOM values close to 
10.0. FOM values higher or lower than 10.0 re-
spectively correspond to treatments which over-
all are likely to be better or worse than the ref-
erence. No special robustness is claimed for the 
proposed scoring system, but the method never-
theless allows the ranking of treatment options 
such that the least satisfactory may be identiﬁ ed 
and rejected.
AIM
The aim of the present study was to apply the 
FOM concept to high dose rate interstitial 
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brachytherapy treatments delivered for carcino-
ma of the cervix at the Kidwai Memorial Institute 
of Oncology, Bangalore, in order to evaluate the 
radiobiological quality of the implants.
MATERIALS AND METHODS
Twenty seven patients diagnosed with stage IIIB 
carcinoma of cervix, and who had received cura-
tive radiotherapy in the form of a combination of 
external beam radiotherapy followed by HDR in-
terstitial brachytherapy, were prospectively includ-
ed in this study. External beam radiotherapy was 
delivered as 50Gy in 25 fractions over ﬁ ve weeks 
on a Cobalt-60 teletherapy machine, without 
mid-line shielding. 10–15 days after completing 
external beam radiotherapy, interstitial brachy-
therapy was delivered by the HDR technique us-
ing a Modiﬁ ed Multipurpose Perineal Interstitial 
Template (M-MUPIT) on a Gammamed HDR ma-
chine. Implantation was carried out under gen-
eral anaesthesia. Sixteen to twenty two needles 
were implanted in these cases.
Semi-orthogonal simulation was utilised for re-
constructing the implant. A rectal marker tube 
containing lead balls, and 7cc of contrast me-
dium in a Foley bladder catheter were used for 
simulating these critical organs. Computation of 
dose distribution was carried out on an Abacus 
treatment planning system. Doses were delivered 
5mm from the periphery of the implant along 
the transverse plane. Points in the bladder and 
rectum, receiving the maximum dose rate, were 
used for the evaluation of total dose received by 
these critical organs. Patients received HDR in-
terstitial brachytherapy in 3 to 4 fractions of 4.5 
to 6.0Gy/fraction over 2 to 14 days.
BED values for the prescribed points of the rec-
tum and bladder were evaluated for an LDR ref-
erence treatment with the help of an LDR in-
terstitial brachytherapy equation proposed by 
Dale [10] and the parameters given in Table 1. 
[3,9,14,15,16] The LDR reference treatment 
was taken as 25Gy at a dose rate of 0.4Gy/hr 
(equivalent to 4.5Gy x 4 fractions of HDR). The 
BED to the rectum and bladder was evaluated 
from the mean rectal dose rate/mean prescrip-
tion dose rate ratio and from the mean bladder 
dose rate/mean prescription dose rate ratio ob-
tained from our earlier study [17].
                 BED = (Total dose × RE) (1)
RE = 1 + (2R0l/µ- l) (b/a) [1–e
–lT]–1
{1/2 l[1–e–2lT] – 1/(µ+l) [1 – e–T(µ+ l)]} (2)
The RE value for HDR interstitial brachythera-
py was evaluated with the following equation and 
the parameters given in Table 1.
                            RE = 1+d/(a/b) (3)
Where,
RE = Relative Effectiveness per unit dose;
R0 = initial dose rate in Gy/hr;
l = 0.693/T1/2 = 0.00038915 hr
–1;
µ = repair constant (hr–1);
a/b = tissue speciﬁ c radio-sensitivity parameter (Gy);
d = dose per fraction of HDR treatment.
BED values were corrected for re-population with 
a correction factor:
                                     RCF = KT (4)
Where,
K = re-population coefﬁ cient in Gy/day;
T = overall treatment time in days.
FOM was evaluated with the following method-
ology [11]:
         FOM = [10 (BEDnew/BEDref)tumZ]X (5)
Where,
Z = 2.5 when (BEDnew/BEDref)tum ≥1.0;
Z = 8.0 when (BEDnew/BEDref)tum <1.0;
and X = [(BEDref/BEDnew)critY];
with Y = 2.0 when (BEDnew/BEDref)crit ≥1.05;
Y = 1.0 when (BEDnew/BEDref)crit <1.05.
Criteria α/β (Gy) µ (hr–1) K (Gy/day)
Prescription point (Tumour) 10.0 0.693 0.5
Rectum 3.87 0.46 0.0
Bladder 4.00 0.46 0.0
Table 1. LQ model parameters utilized in the evaluation of BED values [1,4,10,13,18].
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RESULTS
The relationship between the dose per fraction 
of HDR interstitial brachytherapy and BED to the 
prescription point is shown in Figure 1. As the 
dose per fraction increased from 4.5Gy to 6Gy, the 
BED to the prescription point increased slight-
ly. One patient with a dose per fraction of 4.5Gy 
received a BED of 31.1Gy to prescription point. 
Table 2 shows the BED values for the prescription 
points, the rectum and the bladder and FOM val-
ues for the rectum and bladder. The BED values 
for the prescription point varied from 19.3Gy to 
31.1Gy (Mean 24.3Gy, SD 2.6Gy) for new treat-
ments. BED values for the rectum and bladder 
varied from 12.2Gy to 37.8Gy (Mean 24.7Gy, SD 
7.4Gy) and from 14.8Gy to 39.4Gy (Mean 25.4Gy, 
SD 7.5Gy) respectively. The BED values for ref-
erence treatments to the prescription point, rec-
tum and bladder were 27Gy, 22Gy, and 23Gy re-
spectively.
The relationship between the rectal dose ver-
sus BED (rectum) and bladder dose versus BED 
(bladder) are highlighted in Figures 2 and 3 re-
spectively. The rectal and bladder BED values 
increased with increases to the total cumulative 
dose delivered to these critical organs. The FOM 
values for the rectum and bladder are tabulated 
in Table 2. Two patients had rectal FOM values 
greater than 10. A FOM value higher than 10 for 
the bladder was observed in six patients. Only in 
one patient were values for both the FOM for the 
rectum and the FOM for the bladder above 10. 
Figures 4 and 5 depict the relationship between 
the critical organ dose – prescription dose ratio 
and FOM values for the rectum and bladder re-
spectively. The FOM values maximized with de-
creases to the above said ratio for both the rec-
tum and the bladder.
The relationship between the FOM for the rec-
tum and the FOM for the bladder is shown in 
Figure 6. Most of the FOM values were clustered 
near the initial portion of this scattergram. For 
one patient, the FOM for the rectum was above 
10, while the FOM for the bladder was signiﬁ -
cantly smaller. For another patient, having a sig-
niﬁ cantly higher FOM value for the bladder, the 
FOM value for the rectum was also above the crit-
ical value of 10.
DISCUSSION
The use of the LQ model for the intracavitary 
brachytherapy of cervical cancer is frequent 
[3–8]. There have been a few reports in the lit-
erature regarding the application of biological 
effect models to LDR interstitial brachythera-
py for head and neck cancer [2,18]. Biological 
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Figure 3. Bladder dose vs. BED to bladder.
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treatment planning has been suggested for HDR 
interstitial brachytherapy by a few authors [19,16]. 
However, these methodologies have not been uti-
lised in interstitial brachytherapy for carcinoma 
of the cervix.
Ogino et al. [4] studied late rectal complications 
following high-dose-rate intracavitary brachyther-
apy for cancer of the cervix in 253 patients. The 
rectal point (RP) was deﬁ ned according to the 
criteria recommended in the ICRU 38. The time-
dose factor (TDF) and the biologically effective 
dose (BED) were calculated as components of the 
cumulative rectal reference dose using the rectal 
reference point dose in intracavitary brachythera-
py combined with the external whole pelvis dose. 
Statistical comparison of factors affecting the in-
cidence of late rectal complications was conduct-
ed using data from 161 patients. The incidence 
of late rectal complications among this group was 
9 of the 161 patients (5.6%) for grade I, 51 pa-
tients (31.7%) for grade II, 11 patients (6.8%) 
for grade III, and 13 patients (8.1%) for grade 
IV. The TDF and BED values were signiﬁ cantly 
BED Pre. point (new) BED rectum (new) BED bladder (new) FOMR rectum FOMB ladder
25.1 28.6 32.0 2.8 2.4
25.1 23.4 38.5 4.8 1.8
25.1 18.8 36.7 7.1 1.9
25.1 12.5 39.4 19.1 1.8
25.1 30.4 22.1 2.5 5.5
25.1 25.8 16.4 3.5 10.0
25.1 27.5 15.9 3.0 10.8
25.1 24.3 23.7 4.1 4.9
25.1 20.3 17.1 6.1 9.1
25.1 37.8 30.4 1.8 2.6
21.1 18.2 25.7 1.3 1.2
21.1 32.4 20.6 1.1 1.3
20.6 12.2 34.9 1.1 1.0
21.6 15.4 28.9 1.9 1.3
20.1 18.1 22.4 0.8 0.9
19.6 30.5 22.0 0.8 0.7
21.1 14.8 23.7 1.4 1.3
19.3 23.2 24.2 0.6 0.6
24.1 37.0 17.3 1.6 5.8
31.1 21.9 16.7 15.1 38.5
24.6 31.8 38.5 2.1 1.7
24.6 34.6 30.4 1.9 2.4
24.6 19.5 14.8 5.5 10.0
24.6 23.4 22.6 4.1 4.5
24.6 20.9 26.6 4.9 3.1
27.8 29.9 23.4 3.8 10.3
27.8 33.4 21.9 2.9 12.0
Table 2. BED values at the prescription point, rectum and bladder and FOM values for the rectum and bladder.
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correlated with the incidence of late rectal com-
plications, and also showed strong correlation 
(r=0.976) with each other. Grade IV rectal com-
plications were not observed in any patients with 
TDF values below 130 or BED values below 147. 
The calculated incidence of complications ranged 
from 5 to 10% at TDF values from 104 to 124 and 
at BED values from 119 to 146. The author con-
cluded that, according to his data, studies into 
the incidence of rectal complications may be use-
ful in reducing the incidence of such complica-
tions arising after HDR-ICR treatments for can-
cers of the uterine cervix. This could be done by 
adjusting the dose per fraction and number of 
fractions of HDR-ICR in individual patients, and 
by improving techniques for the insertion of the 
intracavitary radiation apparatus.
Roeske et al. [20] analysed late rectal complica-
tions, following deﬁ nitive radiation therapy for 
carcinoma of the uterine cervix, in 183 patients. 
Treatments consisted of external beam pelvic ra-
diotherapy (EBRT) (median dose: 45Gy, typically 
delivered in fractions of 1.6 to 2Gy) followed by 
intracavitary radiotherapy (ICRT) consisting of 
one or two insertions. The total prescribed point 
A dose ranged from 75 to 90Gy. Conventional to-
tal rectal doses were obtained by adding together 
the EBRT and ICRT rectal doses. To account for 
differences in dose rates between the ICRT and 
EBRT methods, and for variations in the EBRT 
fractionation schemes, biologically equivalent rec-
tal doses (BED) were calculated using the line-
ar quadratic model. The inﬂ uence of varying the 
proportions of EBRT and ICRT rectal doses were 
evaluated. Twenty eight patients developed late 
rectal sequelae. Diabetes, point A, and conven-
tional EBRT doses were the most signiﬁ cant fac-
tors in the multivariate analysis. Logistic regres-
sion analysis demonstrated a low risk (<10%) of 
late rectal sequelae below conventional and bio-
logical rectal doses of 75Gy and 135 BED respec-
tively. The percentage of rectal dose delivered by 
EBRT signiﬁ cantly inﬂ uenced the dose-response 
relationship. A deﬁ nitive threshold percentage 
above which rectal sequelae were more common 
was identiﬁ ed over the range of doses evaluated. 
The threshold was 87% at a total rectal dose of 
60Gy and decreased to 60% at 80Gy. The author 
concluded that the volume of rectum irradiated 
is an important and independent parameter in 
the development of late rectal sequelae.
Clark et al. [3] predicted late complications in 
patients treated by high-dose-rate brachytherapy 
for carcinoma of the cervix in 43 patients treat-
ed with concomitant irradiation and chemother-
apy (Cisplatin 30 mg/m2 given weekly through-
out the duration of the irradiation). To date, the 
results have been compared with those from 119 
patients treated with radiation alone, in order to 
assess the confounding effects of cisplatin. The 
biological effective dose received by each patient 
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at the rectal reference point, as deﬁ ned by the 
ICRU 38, was calculated. Radiotherapy consist-
ed of 46Gy external beam irradiation plus three 
high-dose-rate intracavitary treatments of 10Gy 
each, and delivered to point A. The relation-
ship between the biologically effective dose de-
livered to the rectal reference point and the de-
velopment of late complications showed a strong 
dose-response with a threshold for complications 
occurring at approximately 125Gy, correspond-
ing to a brachytherapy dose of approximately 
8Gy per fraction. This value is approximately the 
same biologically effective dose threshold as that 
found for external beam irradiation in the head 
and neck region. The data from the group of pa-
tients treated without cisplatin is comparable to 
that from the ﬁ rst group of patients in the lower 
dose ranges; higher doses were not used and thus 
are not available for comparison. Applying the 
linear quadratic model to clinical results, authors 
have established a threshold for late rectal com-
plications for patients treated with external beam 
irradiation and with high-dose-rate brachythera-
py for carcinoma of the cervix. The threshold is 
consistent with similar data for external beam ir-
radiation in the head and neck region.
Ferrigno et al. [20] retrospectively analysed dose 
effectiveness and late complications in high-dose-
rate brachytherapy among 138 patients treated 
for cancer of the uterine cervix. Median exter-
nal beam radiotherapy to the whole pelvis was 
45Gy in 25 fractions. Parametrial boost was per-
formed in 93% of cases, with a median dose of 
14.4Gy. Brachytherapy by HDR was performed 
during external beam radiotherapy, or following 
its completion, with a dose of 24Gy in four weekly 
fractions of 6Gy to point A. Median overall treat-
ment time was 60 days. The cumulative biologic 
effective doses (BED) at the rectal and bladder 
reference points were correlated with late com-
plications in these organs and the dose of exter-
nal beam radiotherapy at the parametrium was 
found to correlate with small bowel complica-
tions. Overall survival, disease-free survival, and 
local control at 5 years were 53.7%, 52.7% and 
62% respectively. By multivariate and univariate 
analysis, overall treatment time up to 50 days was 
the only statistically signiﬁ cant adverse variable for 
overall survival and actuarial local control. The 
5-year actuarial incidence of rectal, bladder and 
small bowel late complications were 16%, 11% 
and 14% respectively. Patients treated by cumu-
lative BED at rectum points above 110Gy3 and at 
bladder points above 125Gy3 had a higher, but 
not statistically signiﬁ cant, 5-year actuarial rate of 
complications in these organs. Patients who re-
ceived parametrial doses larger than 59Gy had a 
higher 5-year actuarial rate of complications in 
the small bowel; however, this was not statistical-
ly signiﬁ cant. The authors concluded that 45Gy 
to the whole pelvis, combined with four fractions 
of 6Gy to point A with HDR brachytherapy, is an 
effective and safe fractionation schedule in the 
treatment of stage II and III cancer of the cervix 
if realized within 50 days. To decrease small bow-
el complications, the authors suggested decreas-
ing the superior border of the parametrial ﬁ elds 
to the S2-S3 level and the total dose to 54Gy.
Sakata et al. [6] examined the incidence of radi-
ation-induced late rectal complications by ana-
lysing measured rectal dose data in patients with 
cancer of the uterine cervix, treated with high-
dose-rate intracavitary brachytherapy. Doses were 
measured in 105 patients with cancer of the cer-
vix during high-dose-rate intracavitary brachyther-
apy, using a semiconductor dosimeter that can 
measure ﬁ ve points in the rectum simultaneous-
ly. On basis of these measurements, equivalent 
doses, to which the biologically equivalent doses 
were converted as if given as fractionated irradia-
tion at a rate of 2Gy/fraction, were calculated as 
components of the cumulative dose at ﬁ ve rectal 
points in intracavitary brachytherapy combined 
with the external whole pelvic dose. The calcu-
lated values of equivalent doses for late effects 
at the rectum ranged from 15 to 100Gy (median 
60Gy for patients who did not develop compli-
cations and 76Gy for patients who subsequently 
developed grade II and III complications). The 
data showed a very deﬁ nite dose-response rela-
tionship, with a threshold for complications at ap-
proximately 50Gy and the curve starting to rise 
more steeply at approximately 60Gy. The steep-
est part of the curve had a slope equivalent to 
approximately 4% incidence for every 1Gy in-
crease in equivalent doses. The radiation toler-
ance doses, 5% and 50% complication probabili-
ty, were about 64 and 79Gy, respectively. The data 
almost agree with the prescribed dose for rectal 
radiation tolerance on the basis of recorded hu-
man and animal data. The probability of rectal 
complications increased drastically after reach-
ing maximal rectal doses of >60Gy.
Sood et al. [7] studied the predictive value of the 
linear-quadratic model in the treatment of cervical 
cancer using high-dose-rate brachytherapy. The 
purpose of the study was to determine, retrospec-
tively, whether a dose-response relationship exist-
ed between the biologic effective dose (BED) at 
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point A, the bladder, the rectum and the clinical 
outcomes. This was based on the authors’ expe-
riences with external beam radiotherapy (EBRT) 
and high-dose-rate-brachytherapy in the treatment 
of cervical cancer in 49 patients. Median EBRT 
dose was 45Gy (range: 41.4 to 50.4Gy) and the 
high-dose-rate-brachytherapy median dose was 
18Gy (range: 18 to 19Gy) in two fractions. Twenty 
three patients received concomitant cisplatin-
based chemotherapy. The cumulative BEDs were 
calculated at point A (BED10) and at the bladder 
and rectal reference points (BED3) using the lin-
ear-quadratic equation. In patients treated with 
RT alone, the local failure rate was 10%. The fail-
ure rates were 19% in patients receiving a BED10 
>89Gy10 or <89Gy10 to point A, respectively. The 
corresponding local failure rates were 20% and 
0% in patients treated with concomitant chemo-
therapy. In patients treated with RT alone, the lo-
cal failure rate was 7.7% and 23% in patients with 
a BED10tf (BED including time factor) >64Gy10 or 
<64Gy10, respectively. The median BED3 values at 
the rectal and bladder points were 95.5Gy3 and 
103.6Gy3, respectively. Only 1 case of grade II late 
rectal toxicity was recorded and no cases of late 
bladder toxicity occurred. In patients treated with 
RT alone, a BED10tf > 89Gy10 and a BED10tf > 64Gy10 
indicated a trend towards a better local control 
rate. This difference was not observed in patients 
receiving chemotherapy. A BED3 <100Gy3 was as-
sociated with negligible late toxicity. Although 
the BED10 in this study was about 10–15Gy10 less 
than that in the published literature, the 4-year 
local control rates of 80% and 83% and disease-
free survival rate of 75% and 70% with and with-
out chemotherapy, respectively, compare well with 
the rates in other studies in the literature.
Toita et al. [8] determined the dose and frac-
tionation schedule for a combination of external 
beam radiotherapy (EBRT) and high-dose-rate in-
tracavitary brachytherapy (HDR-ICBT) for uter-
ine cervical cancer in 88 patients. Twenty-ﬁ ve pa-
tients were classiﬁ ed as early disease (non-bulky 
stage I/II, less than 4-cm diameter) and 63 pa-
tients as advanced disease (greater than 4cm di-
ameter or stage IIIB), according to the ABS deﬁ -
nition. The median cumulative point A dose (the 
sum of the EBRT midline dose and the point A 
dose of ICBT) was 58Gy (range: 24–64Gy). Pelvic 
EBRT was delivered before application of ICBT. 
HDR-ICBT was performed once a week, with a 
fractional point A dose of 6Gy. No planned opti-
mization was carried out. The median cumulative 
biologic effective dose (BED) at point A (EBRT + 
ICBT) was 64.8Gy10 (range: 48–76.8Gy10) for early 
disease, and 76.8Gy10 (range: 38.4–86.4Gy10) for 
advanced disease. The median cumulative BED 
at ICRU 38 reference points (EBRT + ICBT) were 
97.7Gy3 (range: 59.1–134.4Gy3) at the rectum, 
97.8Gy3 (range: 54.6–130.4Gy3) at the bladder, 
and 324Gy3 (range: 185.5–618Gy3) at the vagina. 
Actuarial pelvic control rates and late complica-
tion rates were analysed according to cumulative 
doses and calculated BEDs. The 3-year actuarial 
pelvic control rate was 82% for all 88 patients: 
96% for those with early disease, and 76% for ad-
vanced disease. For pelvic control, no signiﬁ cant 
dose-response relationship was observed in the 
treatment schedules or cumulative BED at point 
A for either early or advanced disease. The 3-year 
actuarial late complication rates (grade ≥1) were 
12% for proctitis, 11% for cystitis, and 14% for 
enterocolitis. The authors suggested that a cu-
mulative BED of 70–80Gy10 at point A is appro-
priate for uterine cervical cancer patients treat-
ed with a combination of EBRT and HDR-ICBT. 
The present study and other data in the litera-
ture suggest that the cumulative BED at the rec-
tal point should be kept below 100–120Gy3 in or-
der to prevent late rectal complication.
Nag et al. [16] developed a simple program that 
can be easily used by clinicians to calculate the tu-
mour and late tissue equivalent doses (as if given 
in 2Gy/day fractions) for different high-dose-rate 
(HDR) brachytherapy regimens. The program ac-
counts for the normal tissue sparing effect of brach-
ytherapy. Since doses given to normal tissues in 
HDR brachytherapy treatments are different from 
those delivered to the tumour, a normal tissue dose 
modifying factor (DMF) (depending on the an-
ticipated dose to normal tissue) was applied in a 
spreadsheet to obtain more realistic equivalent nor-
mal tissue effects. The program requires the clini-
cian to enter only the external beam total dose and 
dose/fraction, HDR dose, and the number of HDR 
fractions. It automatically calculates the equivalent 
doses for the tumour and normal tissue effects, re-
spectively. Generally, the DMF applied is <1 since 
the doses to normal tissues are less than the doses 
to the tumour. However, in certain circumstances 
a DMF of >1 may need to be applied if the dose to 
normal critical tissues is higher than the dose to 
the tumour. Additionally a/b ratios for tumours 
and normal tissues can be changed from their de-
fault values of 10Gy and 3Gy, respectively. This 
program has been used to determine HDR doses 
needed for the treatment of cancers of the cervix, 
prostate, and other organs. It can also been used 
to predict late normal tissue effects, thus alerting 
the clinician to the possibility of undue morbidity 
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associated with a new HDR regimen. The novelty 
of this program is that the equivalent doses are ex-
pressed as if given at 2Gy per fraction rather than 
as BED values and a more realistic equivalent nor-
mal tissue effect is obtained by the application of 
a DMF. The author concluded that the use of his 
method should promote the use of LQ radiobio-
logical modeling to determine doses to be used for 
HDR brachytherapy. The author also warned that 
the program should be used as a guide only and 
should be correlated with clinical outcome.
Manning et al. [19] studied the application of radi-
obiological principles to account for the potential 
biological impact of dose delivery at varying dose 
rates within an HDR implant. The model under 
study used a generalized version of the linear-quad-
ratic (LQ) cell kill formula to calculate the surviv-
ing fraction of cells subjected to HDR irradiation. 
Using a planar interstitial HDR implant with the 
dwell times optimized, to produce a homogene-
ous dose distribution along a reference plane par-
allel to the implant plane, surviving fractions were 
compared at selected reference points subjected 
to the same total dose. The homogeneity of bio-
logical effects was compared to the homogeneity 
of dosage by plotting the effects at the reference 
points. The effects were examined with LQ param-
eters a,b, and sub-lethal repair time T1, which was 
varied over a range typical of human cells. In re-
gions in which the dose was relatively uniform, the 
surviving fraction for some values of the model pa-
rameters were found to vary by as much as an order 
of magnitude, owing to differences in the HDR ir-
radiation proﬁ les at different dose points. This ef-
fect was more pronounced for shorter times and 
smaller a/b rations, and increased with increas-
ing total irradiation time. Conventional HDR treat-
ment planning currently considers dose distribu-
tion to be the primary indicator of clinical effects. 
These results demonstrated that plans optimized 
to maximize homogeneity within a target volume 
may not reﬂ ect the effect of the sequential nature 
of HDR dose delivery on cell killing. The author 
concluded that biological effect modeling may 
improve our understanding of, and our ability to 
predict, the adverse effects of treatment, such as 
fat necrosis and ﬁ brosis. The author also suggest-
ed that accounting for irradiation history and re-
pair kinetics in the evaluation of HDR brachyther-
apy plans may add an important new dimension 
to planning capabilities.
Mazeron et al. [2] studied the effects of dose rate 
on local control and complications in the deﬁ nitive 
irradiation of 279 T1-2 squamous cell carcinomas of 
the mobile tongue and the ﬂ oor of the mouth with 
interstitial iridium-192 implants. The dose was not 
adjusted for dose rate. The reference dose was taken 
as 85% of the basal dose. The total dose delivered 
was between 60 and 70Gy. The results showed that 
local control is signiﬁ cantly related to dose and is in-
dependent of the dose rate; the local control dose-
effect curve reached a plateau above approximate-
ly 62.5Gy while reducing the dose below 62.5Gy led 
to a rapid increase in local failures. Necrosis is sig-
niﬁ cantly related to dose when the dose rate is less 
than 0.5Gy per hour. Local control is dose-rate de-
pendent only below 62.5Gy. Necrosis is related to 
dose rate, but independent of dosage. Dose correc-
tion may lead to an increase in the local failure rate 
without causing a reduction in necrosis. Also, dose 
rate correction may reduce necrosis without reduc-
ing local control. A multivariate analysis revealed 
that dose, dose rate and tumour diameter signiﬁ -
cantly inﬂ uenced local control while only tumour 
diameter and site inﬂ uenced the risk of necrosis. 
A trend towards a signiﬁ cant relationship between 
the dose rate and necrosis was observed. To maxi-
mize local control whilst minimizing necrosis, the 
author recommended a dose of 65–70Gy at a dose 
rate of 0.3–0.5Gy/hr.
Local control and necrosis were correlated with 
ERD. Statistical calculations showed that local 
control and necrosis are related to ERD. ERD 
was also evaluated, along with other values for 
a/b (1–25Gy) and T1/2 (0.5–1.5 hr). No signiﬁ -
cant inﬂ uence of these modiﬁ cations to the ERD 
were demonstrated on either the distribution of 
patients according to local control or necrosis.
Pernot et al. [18] studied the inﬂ uence of tumour 
related, radiobiological and general factors on lo-
cal control and survival in a series of 361 tumours 
of the velotonsillar area treated exclusively by irra-
diation. 18 patients received brachytherapy alone 
and 343 patients received a combination of ex-
ternal beam irradiation and brachytherapy. All 
the brachytherapy cases were treated using Ir-192 
sources. The results after 5 and 10 years showed 
local control in 80% and 74%, loco-regional con-
trol in 75% and 70%, overall survival in 53% and 
27%, speciﬁ c survival in 63% and 52%, respec-
tively. The radiobiological factors (ERD) showed 
less recurrences if the total duration of the treat-
ment was <55 days and the number of days be-
tween external beam irradiation and brachyther-
apy was <20 days. The authors concluded that 
for a combination of external beam irradiation 
and brachytherapy, the stage and localization of 
the tumour and the total duration of treatment 
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are signiﬁ cant. For complications , classiﬁ ed into 
four grades, only the dose rate was found to be 
signiﬁ cant.
CONCLUSIONS
We evaluated FOM values for the rectum and blad-
der on the basis of formulae suggested by Dale and 
Sinclair. Two patients had a FOM rectum value 
greater than 10. A FOM value for bladder higher 
than 10 was observed in six patients. Only in one pa-
tient were FOM values for both the rectum and the 
bladder above 10. The FOM values maximized with 
decreases to the critical organ dose to prescription 
dose ratios for both the rectum and bladder.
Good physical optimization can lead to good ra-
diobiological optimization. Radiobiology can not 
improve on a bad quality implant. HDR intersti-
tial brachytherapy, which gives better geometri-
cal sparing for critical normal organs such as the 
rectum and bladder, should be the treatment of 
choice for cervical cancer patients. In optimiz-
ing treatment for a patient, maximization of the 
FOM value should be supplemented by compar-
ison with reference BED values and new treat-
ments for the rectum and bladder. 
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